[go: up one dir, main page]

NO20084488L - Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith - Google Patents

Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith

Info

Publication number
NO20084488L
NO20084488L NO20084488A NO20084488A NO20084488L NO 20084488 L NO20084488 L NO 20084488L NO 20084488 A NO20084488 A NO 20084488A NO 20084488 A NO20084488 A NO 20084488A NO 20084488 L NO20084488 L NO 20084488L
Authority
NO
Norway
Prior art keywords
treatment
functional protein
methods
dna
production
Prior art date
Application number
NO20084488A
Other languages
English (en)
Inventor
Seongwoo Hwang
Guangming Chen
Young-Choon Moon
Hongyu Ren
Samit Hirawat
Langdon Miller
Neil G Almstead
Gary M Karp
James J Takasugi
Ellen M Welch
Richard G Wilde
Paul Kennedy
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of NO20084488L publication Critical patent/NO20084488L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår det funksjonelle proteinet kodet av nukleinsyresekvenser som innbefatter en ikke-sensmutasjon. Foreliggende oppfinnelse angår også fremgangsmåter for produksjon av funksjonelle proteinet kodet av nukleinsyresekvenser som innbefatter en ikke-sensmutasjon og anvendelsen av slike proteinet for hindring, håndtering og/eller behandling av sykdommer assosiert med ikke-sensmutasjoner i et gen.
NO20084488A 2006-03-30 2008-10-24 Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith NO20084488L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78733306P 2006-03-30 2006-03-30
US81308506P 2006-06-12 2006-06-12
PCT/US2007/008268 WO2007117438A2 (en) 2006-03-30 2007-03-29 Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith

Publications (1)

Publication Number Publication Date
NO20084488L true NO20084488L (no) 2008-12-19

Family

ID=38480572

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084488A NO20084488L (no) 2006-03-30 2008-10-24 Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith

Country Status (15)

Country Link
US (2) US9289398B2 (no)
EP (2) EP2007365A2 (no)
JP (2) JP5367563B2 (no)
CN (1) CN101505739A (no)
AU (1) AU2007235524B2 (no)
BR (1) BRPI0710213A2 (no)
CA (1) CA2647903C (no)
IL (2) IL194454A (no)
IN (1) IN2014CN04406A (no)
MX (1) MX2008012515A (no)
NO (1) NO20084488L (no)
NZ (2) NZ571899A (no)
RU (1) RU2462246C2 (no)
SG (1) SG170819A1 (no)
WO (1) WO2007117438A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009120B1 (ru) 2003-04-11 2007-10-26 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения 1,2,4-оксадиазолбензойной кислоты и их применение
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2010123369A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
EP2251437B1 (en) 2009-05-13 2013-12-04 Hannelore Breitenbach-Koller Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
JP2015509922A (ja) 2012-01-27 2015-04-02 プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド
EP2928471B1 (en) 2012-12-06 2020-10-14 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN103074346A (zh) * 2013-01-22 2013-05-01 山西大学 一种用于促通读药物筛选的有限细胞株的建立方法
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
TWI636978B (zh) * 2014-03-06 2018-10-01 美商Ｐｔｃ治療公司 １，２，４－二唑苯甲酸之鹽及醫藥組合物
JP6543268B2 (ja) * 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
JP2016155900A (ja) * 2015-02-23 2016-09-01 株式会社フジミインコーポレーテッド 研磨用組成物、研磨方法及び硬脆材料基板の製造方法
TW201729807A (zh) 2015-10-30 2017-09-01 Ｐｔｃ治療公司 用於治療癲癇的方法
US10898483B2 (en) 2015-12-23 2021-01-26 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
EP3512516A1 (en) * 2016-09-13 2019-07-24 Marco Cipolli Method of treatment of shwachman-diamond syndrome
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
CN107916252B (zh) * 2017-11-17 2021-01-22 首都儿科研究所 一株用于验证脊肌萎缩症的永生淋巴细胞株
EA202192767A1 (ru) * 2019-04-10 2021-12-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ лечения опосредуемой нонсенс-мутацией мышечной дистрофии дюшенна у педиатрических пациентов

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (no) 1962-04-17
US3325446A (en) 1964-04-17 1967-06-13 Allied Chem Stabilized halogen-containing olefin polymer compositions and stabilizers therefor
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
JPS51143669A (en) 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
US4016170A (en) 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4166732A (en) 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
EP0036711B1 (en) 1980-03-22 1985-12-04 Fbc Limited Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
DE3148449C1 (de) 1981-12-08 1983-06-01 Heidelberger Druckmaschinen Ag, 6900 Heidelberg Verfahren zur Verringerung von Registerfehlern und Druckmaschine zur Durchfuehrung des Verfahrens
GB8802142D0 (en) 1988-02-01 1988-03-02 Air Prod & Chem Method of freezing liquid & pasty products & freezer for carrying out said method
US5037052A (en) 1989-04-21 1991-08-06 Crisp Joe E Clamp assembly system
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5036761A (en) 1989-11-20 1991-08-06 Wingo Patrick Y Forced flow press dampening apparatus
US4984286A (en) 1989-12-12 1991-01-08 Analogic Corporation Spatial filter system
US5036762A (en) 1990-06-12 1991-08-06 Sarda Jean Lucien Apparatus for supplying offset printing presses with a cooled damping solution
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
ES2154637T3 (es) 1991-05-14 2001-04-16 Univ Connecticut Aportacion de genes dirigidos que codifican proteinas inmunogenicas.
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
DE69330167T2 (de) 1992-10-09 2001-11-15 Advanced Tissue Sciences, Inc. Leberreservezellen
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
DE4320801A1 (de) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
RU2164419C2 (ru) * 1994-03-18 2001-03-27 Мириад Дженетикс, Инк. Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
PL324987A1 (en) 1995-09-07 1998-07-06 Ciba Geigy Ag Substituted phosphonic compounds and their application as pharmaceutic agents
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
AU712057B2 (en) 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
EP0975595B9 (en) 1997-04-07 2009-09-16 Georgetown University Analogs of cocaine
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
RU2191777C2 (ru) * 1998-02-26 2002-10-27 Авентис Фармасьютикалз Инк. 6,9-дизамещенные 2-[транс-(-4-аминоциклогексил)амино]пурины
IL139187A0 (en) 1998-04-23 2001-11-25 Cortech Inc Cysteine protease inhibitors
DE69914931T2 (de) 1998-10-09 2004-12-16 Janssen Pharmaceutica N.V. 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung
EP1126833A4 (en) 1998-10-29 2004-09-08 Trega Biosciences Inc OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES
HUP0104768A3 (en) 1998-12-23 2002-05-28 Smithkline Beecham Corp 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
EP1157274A1 (en) * 1999-03-02 2001-11-28 The University of Dundee Methods of determining altered ndpk functions
WO2000058280A1 (fr) 1999-03-26 2000-10-05 Shionogi & Co., Ltd. Derives de sulfonamide carbocyclique
AU3196100A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
AU3196200A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Beta-amino acid derivatives
ATE307798T1 (de) 1999-05-17 2005-11-15 Novo Nordisk As Glucagon antagonisten/inverse agonisten
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
AU2001243987A1 (en) 2000-03-22 2001-10-03 Merck Frosst Canada & Co. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
AU2001257413B2 (en) 2000-05-22 2007-01-18 Aventisub Llc Arylmethylamine derivatives for use as tryptase inhibitors
US7366402B2 (en) 2000-06-02 2008-04-29 Lg Electronics Inc. Method and apparatus of recording a high definition digital television broadcast signal
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
US7115612B2 (en) 2001-04-19 2006-10-03 Bayer Aktiengesellschaft Arylsulfonamides as antiviral agents
KR20040004705A (ko) 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
WO2004001010A2 (en) 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
EP1525185A1 (en) 2002-07-24 2005-04-27 PTC Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
AU2003252136A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2004009558A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
JP2006502134A (ja) 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体において活性を有する化合物
EP1536790A2 (en) 2002-08-09 2005-06-08 AstraZeneca AB Oxadiazoles as modulators of metabotropic glutamate receptor-5
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7555125B2 (en) 2003-08-14 2009-06-30 Broadcom Corporation Systems and methods for generation of time-dependent control signals for video signals
EA009120B1 (ru) * 2003-04-11 2007-10-26 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения 1,2,4-оксадиазолбензойной кислоты и их применение
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
JP3852934B2 (ja) 2003-05-20 2006-12-06 株式会社バンダイナムコゲームス 画像処理システム、プログラム及び情報記憶媒体
US20050037052A1 (en) 2003-08-13 2005-02-17 Medtronic Vascular, Inc. Stent coating with gradient porosity
KR100565056B1 (ko) 2003-08-14 2006-03-30 삼성전자주식회사 Ａｖ 데이터를 ｅｎａｖ 모드로 재생하는 방법, 그 장치및 그 정보저장매체
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005086768A2 (en) * 2004-03-11 2005-09-22 Albert Einstein College Of Medicine Of Yeshiva University Enhanced production of functional proteins from defective genes
DE102004013599A1 (de) * 2004-03-19 2005-10-06 Robert Bosch Gmbh Ansteuerschaltung zum Ansteuern einer leistungselektronischen Schaltung sowie Verfahren hierzu
EP2402323A3 (en) * 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
PT2402002T (pt) 2005-04-08 2018-10-08 Ptc Therapeutics Inc Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense
PL2059513T3 (pl) 2006-09-08 2013-06-28 Ptc Therapeutics Inc Sposób wytwarzania pochodnych 1,2,4-oksadiazolowych kwasu benzoesowego
WO2008130370A1 (en) 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
JP5714228B2 (ja) 2006-09-25 2015-05-07 ピーティーシー セラピューティクス，インコーポレーテッド ３−［５−（２−フルオロフェニル）−［１，２，４］オキサジアゾール−３−イル］−安息香酸の結晶形
CL2007002923A1 (es) 2006-10-12 2008-06-06 Ptc Therapeutics Inc Soc Organ Metodo para el tratamiento, prevencion o manejo de una enfermedad asociada con una mutacion sin sentido tal como cancer, diabetes o enfermedad pulmonar, que consiste en administrar a un paciente una cantidad efectiva de acido 3-[5-(2-fluoro-fenil)-[1
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy

Also Published As

Publication number Publication date
RU2008142957A (ru) 2010-05-10
IL222557A0 (en) 2012-12-31
BRPI0710213A2 (pt) 2011-04-12
US20160199357A1 (en) 2016-07-14
CN101505739A (zh) 2009-08-12
CA2647903C (en) 2016-12-13
RU2462246C2 (ru) 2012-09-27
IL222557A (en) 2016-09-29
SG170819A1 (en) 2011-05-30
NZ596965A (en) 2013-06-28
JP2009532368A (ja) 2009-09-10
MX2008012515A (es) 2008-11-19
IL194454A0 (en) 2009-08-03
IN2014CN04406A (no) 2015-09-04
WO2007117438A2 (en) 2007-10-18
US9289398B2 (en) 2016-03-22
AU2007235524A1 (en) 2007-10-18
NZ571899A (en) 2012-07-27
EP2007365A2 (en) 2008-12-31
CA2647903A1 (en) 2007-10-18
IL194454A (en) 2013-01-31
EP2387995A1 (en) 2011-11-23
JP5367563B2 (ja) 2013-12-11
JP5798154B2 (ja) 2015-10-21
US20110046136A1 (en) 2011-02-24
AU2007235524B2 (en) 2013-09-12
JP2013234189A (ja) 2013-11-21
WO2007117438A3 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
NO20084488L (no) Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2007087451A3 (en) Compositions and methods for enhancing discriminatory rna interference
WO2009059318A3 (en) Genes and polymorphisms associated with amd
DK2049664T3 (da) Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
WO2008132723A3 (en) Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
WO2009090639A3 (en) Sirna compounds and methods of use thereof
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
EP2639319A3 (en) Genetic polymorphisms associated with Psoriasis, methods of detection and uses thereof
WO2008104978A3 (en) Novel sirna structures
WO2010056982A3 (en) Compositions and methods for identifying autism spectrum disorders
WO2009045370A3 (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2007091269A3 (en) NOVEL TANDEM siRNAS
SG179410A1 (en) Therapeutic uses of inhibitors of rtp801
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
MX2013004879A (es) Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
WO2008087641A3 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2011022357A3 (en) Fast acting snare-cleaving enzymes
WO2008143774A3 (en) Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
WO2010011283A3 (en) Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases
DK1730315T3 (da) Polymorphismer i NOD2/Card15 gen
WO2007149521A3 (en) Nucleotide motifs providing localization elements and methods of use
EP4324936A3 (en) Method for detecting cystic fibrosis
WO2009147658A3 (en) Compositions and methods for diagnosis, prognosis and treatment of mesothelioma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application